HomeCompareHBPCF vs SBUX

HBPCF vs SBUX: Dividend Comparison 2026

HBPCF yields 115.61% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HBPCF wins by $7.07M in total portfolio value
10 years
HBPCF
HBPCF
● Live price
115.61%
Share price
$1.73
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.23M
Annual income
$2,676,132.53
Full HBPCF calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — HBPCF vs SBUX

📍 HBPCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHBPCFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HBPCF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HBPCF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBPCF
Annual income on $10K today (after 15% tax)
$9,826.59/yr
After 10yr DRIP, annual income (after tax)
$2,274,712.65/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, HBPCF beats the other by $2,218,748.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBPCF + SBUX for your $10,000?

HBPCF: 50%SBUX: 50%
100% SBUX50/50100% HBPCF
Portfolio after 10yr
$3.69M
Annual income
$1,370,986.32/yr
Blended yield
37.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

HBPCF
No analyst data
Altman Z
17.7
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBPCF buys
0
SBUX buys
0
No recent congressional trades found for HBPCF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHBPCFSBUX
Forward yield115.61%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$7.23M$157.5K
Annual income after 10y$2,676,132.53$65,840.13
Total dividends collected$6.55M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: HBPCF vs SBUX ($10,000, DRIP)

YearHBPCF PortfolioHBPCF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$22,261$11,560.69$11,107$407.21+$11.2KHBPCF
2$47,870$24,051.31$12,512$626.87+$35.4KHBPCF
3$99,558$48,337.27$14,366$978.69+$85.2KHBPCF
4$200,481$93,953.00$16,929$1,557.50+$183.6KHBPCF
5$391,330$176,815.76$20,658$2,543.80+$370.7KHBPCF
6$741,281$322,558.19$26,406$4,302.22+$714.9KHBPCF
7$1,364,208$571,036.96$35,877$7,622.00+$1.33MHBPCF
8$2,441,853$982,150.40$52,741$14,352.64+$2.39MHBPCF
9$4,255,766$1,642,983.32$85,676$29,243.03+$4.17MHBPCF
10$7,229,802$2,676,132.53$157,513$65,840.13+$7.07MHBPCF

HBPCF vs SBUX: Complete Analysis 2026

HBPCFStock

Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Full HBPCF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this HBPCF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBPCF vs SCHDHBPCF vs JEPIHBPCF vs OHBPCF vs KOHBPCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.